STOCK TITAN
  1. Home
  2. News
  3. AMPH

Amphastar Pharmaceuticals Inc - AMPH STOCK NEWS

Welcome to our dedicated news page for Amphastar Pharmaceuticals (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amphastar Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amphastar Pharmaceuticals's position in the market.

News
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) executives to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
News
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (AMPH) executives to present at Barclays 26th Annual Global Healthcare Conference on March 13, 2024. Webcast accessible on company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
-
News
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) reported strong financial results for the fourth quarter and full-year ended December 31, 2023. Net revenues reached $178.1 million for the quarter and $644.4 million for the year. GAAP net income was $36.2 million for the quarter and $137.5 million for the year. Adjusted non-GAAP net income was $46.9 million for the quarter and $175.7 million for the year. The company highlighted the success of its products, including glucagon, Primatene MIST, and the recent submission of its first BLA for Insulin Aspart.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.93%
Tags
earnings
News
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will release its Q4 2023 results on February 28, 2024. The company focuses on developing and selling generic and proprietary injectable, inhalation, and intranasal products, along with insulin API products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
earnings
-
News
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that CEO Dr. Jack Zhang and CFO Bill Peters will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 9:00 am PST. The webcast will be available for 30 days on Amphastar's Pharmaceuticals website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences
-
News
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. The webcast will be available for 90 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
conferences
News
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced CFO Bill Peters and EVP Jacob Liawatidewi will join a fireside chat at Jefferies London Healthcare Conference on Nov 15, 2023. The webcast will be accessible on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
conferences
-
News
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) reported net revenues of $180.6 million for the three months ended September 30, 2023. The company also announced GAAP net income of $49.2 million and adjusted non-GAAP net income of $61.9 million for the same period. The strong results were attributed to the success of the diabetes portfolio, including the strategic acquisition of BAQSIMI® and the continued strength of the generic glucagon product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.39%
Tags
earnings
-
News
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
Rhea-AI Summary
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will release its Q3 2023 results on November 8, 2023. The company focuses on developing, manufacturing, and selling generic and proprietary injectable, inhalation, and intranasal products. They also sell insulin API products. Most of their products are used in hospital or urgent care settings and are distributed through group purchasing organizations and drug wholesalers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
earnings
News
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
Rhea-AI Summary
Amphastar Pharmaceuticals announces pricing of $300.0 million of convertible senior notes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Stock AMPH logo
Amphastar Pharmaceuticals Inc

Nasdaq:AMPH

AMPH Rankings

#1868 Ranked by Market Cap
#468 Ranked by Stock Gains
N/A Ranked by Dividends

AMPH Stock Data

2.00B
37.54M
22.02%
70.19%
7.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Rancho Cucamonga

About AMPH

amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int